1	2	3
6.	Alembic Chemicals Labs	38,72,747.98
7.	Bombay Drug House	1,73,051.00
8.	Pharmed Pvt. Ltd.	68,00,776.80
9.	Dolphin Labs.	18,10,988.20
10.	Albert David Ltd.	3,91,419.00
11.	Pharmaceuticals & Chemicals Ind.	87,993,26.50
12.	Cadila Labs. Pvt. Ltd.	76,52,433.00
13.	Sarabhai Chemicals	4,13,986.48
14.	Lupin Labs.	2,15,89,000.00
15.	Ranbaxy Labs.	47,77,652.40
16.	Wallace Pharmaceuticals	2,82,071.00
17.	Ethico Drug & Chemical Mfg. Co.	1,40,97,889.00
	DIPHYRIDAMOL	
1.	M/s. German Remedies	59,95,039.00
	GENTAMYCIN	
1.	M/s. Fulford India Ltd. (Court Case)	194.62 Lakhs
2.	M/s. Biochem Pharma Ltd.	33.88 Lakhs
3.	M/s. Lyka Labs Ltd.	27.47 Lakhs

Recovery of DPEA arrears

4590. DR. (SHRIMATI) NAJMA HEPTULLA : Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 3282 given in the Rajya Sabha on the 22nd August, 1988 and State :

(a) whether it is a fact that his Ministry has failed to recover the amount overcharged from the consumers by drug companies under DPEA;

(b) whether it is also a fact that his Ministry has not been able to obain information from the companies o whom notices were sent under the rovision of DPCO, 1979 despite the act that full powers are available to spect and collect information;

(c) whether it is also a fact that his linistry has not been able to work ut the estimated amount due from ie companies; and

(d) if so, what are the reasons therefor ?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO) : (a) No, Sir.

(b) to (d) Many of the companies did not furnish the required details. The amount for which notices issued for recovery have been disputed and representations made. However, the determination of amounts and recovery of the same is a continuous process and appropriate action as per due process of law would be taken.

4591. [*Withdrawn*]

Overcharging of prices on drugs

4592. SHRI DHARANIDHAR BASUMATARI : Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 3308 given in the Rajya Sabha on the 22nd August, 1988 and state :

(a) the names of the drugs on which the overcharged amount has been assessed in respect of the six companies;

(b) what are the reasons for not providing the details of the assessed amount by the committee to the Parliament;

(c) what was the rate on which the amount was assessed by the committee on each drug of each company along with the production of each drug;

(d) whether it is a fact that Parliament has the right to have these details which are of public interest; and

(e) if so, when these details will be provided and the report b laid on the Table of the House?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO) : (a) Information to the extent available is given in the enclosed statement (*See* below).

(b) and (d) Information to the extent available has been furnished to the Parliament under reply to Unstarred Question No. 4632 dated 5th September, 1988.

(c) The details of production and the rate at which the amount was assessed etc. are quite voluminous. The time and efforts required for collection of these details will not be commensurate with the results likely to be achieved.

(e) The calculations and findings of the special team are not required to be laid on the Table of the House.

Statement

Sl. No.	Name of the Company	Name of the bulk drugs/formulations
1.	M/s. Cynamid (I) Ltd.	Tetracycline & Formulations.
2.	M/s. —do—	Diethyl Carbamine formulations.
3.	M/s. Geoffrey Manners & John Wyeth Ltd.	Sonzotnine Pelcillin & its formulations.
4.	M/s. Pfizer Ltd.	Oxytatracycline & its salts & formulations based thereon.
5.	M/s. Hoechst (I) Ltd.	Baralgon, Pyrolidine Methyl Tetrecaycline, Pheniramine, Glyoabclamide, Frusamids and formulations.

Production of Baralgan Ketone

4593. SHRI DHARANIDHAR BASUMATARI : Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred question 3348 given in the Rajya Sabha on the 22nd August, 1988 and state :

(a) what was the price notified by his Ministry of Baralgan Ketone and what price was being charged by the company;

(b) what was the amount assessed by the Committee on this drug only upto the 31st December, 1983;